The French Competition Authority announced its approval for a pending merger between pharmaceutical giants Actavis and Warner Chilcott, say reports. Actavis’s buyout of Warner Chilcott remains pending. The German Federal Cartel Office has similarly cleared the deal and, according to a press release, the parties have now obtained permission from all ex-US antitrust regulators. Financial details of the deal were not made public. Actavis, based in the US, recently went head-to-head with the US Federal Trade Commission in the Supreme Court; the Court found that so-called pay-for-delay deals, which delay cheaper, generic forms of pharmaceuticals from being sold, can be subject to antitrust lawsuits.
Featured News
Geradin Partners Expands Competition Practice with Senior Counsel Hire
Dec 9, 2025 by
CPI
Regulatory Scrutiny Intensifies as EssilorLuxottica Pushes Into AI Eyewear
Dec 9, 2025 by
CPI
Big Law Expands Artificial Intelligence Roles to Stay Competitive
Dec 9, 2025 by
CPI
EU Parliament Report Endorses Compulsory Copyright Licensing for AI Training
Dec 9, 2025 by
CPI
Judge Pushes for Faster Pace in NASCAR Antitrust Trial
Dec 8, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Intellectual Property
Nov 19, 2025 by
CPI
Dealing in Intellectual Property: IP Justifications and Defenses in Digital Markets Cases
Nov 19, 2025 by
Jennifer Dixton
The Evolving Role of Innovation Theories of Harm in the Antitrust Analysis of Life Science Mergers
Nov 19, 2025 by
Michelle Yost Hale, Matthew D. McDonald & Merrill Stovroff
Who Can Fix It? Antitrust, IP Rights, and the Right to Repair
Nov 19, 2025 by
Rosa M. Morales
Copyright, Antitrust, and the Politics of Generative AI
Nov 19, 2025 by
Daryl Lim